Core Outcome Measures in Effectiveness Trials

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

General Information

Abstract:
In 2003, an international working group last reported on recommendations for diagnosis, response assessment, and treatment outcomes in acute myeloid leukemia (AML). Since that time, considerable progress has been made in elucidating the molecular pathogenesis of the disease that has resulted in the identification of new diagnostic and prognostic markers. Furthermore, therapies are now being developed that target disease-associated molecular defects. Recent developments prompted an international expert panel to provide updated evidence- and expert opinion-based recommendations for the diagnosis and management of AML, that contain both minimal requirements for general practice as well as standards for clinical trials. A new standardized reporting system for correlation of cytogenetic and molecular genetic data with clinical data is proposed.

Authors:
Dohner, H. Estey, E. H. Amadori, S. Appelbaum, F. R. Buchner, T. Burnett, A. K. Dombret, H. Fenaux, P. Grimwade, D. Larson, R. A. Lo-Coco, F. Naoe, T. Niederwieser, D. Ossenkoppele, G. J. Sanz, M. A. Sierra, J. Tallman, M. S. Lowenberg, B. Bloomfield, C. D. European, LeukemiaNet

Publication

Journal:
Blood
Volume:
115
Issue:
3
Pages:
453 - 74
Year:
2010
DOI:
Further Study Information

Date:
Not stated
Funding source(s):
This work was supported by the European Union, Sixth Framework Programme, contract no. LSHC-CT-2004-503216 (European LeukemiaNet).

Health Area

Disease Category
Cancer

Disease Name
Leukemia (acute myeloid)

Target Population

Age Range
18 - 100

Sex
Either


Nature / type of Intervention
Not specified

Method(s)

Literature review
Semi structured discussion

Stakeholders Involved

Clinical experts
Researchers

Study Type

Definition

The site uses cookies, some may have been set already. Please refer to our privacy policy & cookie usage statement.
If you continue to use the site we'll assume you're happy to accept the cookies.